Kynexis B.V.

https://www.kynexistx.com

Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. The Company also has a subsidiary in the United States, which is based in Cambridge, Mass. (Kynexis Therapeutics Inc.) *

	Start	2023-11-07 start
	Group	Kynexis (Group)
	Industry	personalised medicine / precision medicine
	Industry 2	CNS drug (neurological drug)
	Person	Been, Kees (Kynexis 202311– CEO formerly EnVivo 200506– CEO before Bionaut CEO + Biogen)
	Person 2	Andersen, Peter Høngaard (Forbion 202207– Operating Partner before Lundbeck + Novo Nordisk et al)

	Region	Naarden
	Country	Netherlands
	City	n. a. Naarden
		Address record changed: 2023-11-16

Basic data	Employees	n. a.

		* Document for »About Section«: Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Kynexis (Group)

[1] Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]